"high Doses Of Riboflavin And The Elimination Of Dietary Red Meat Promote The Recovery Of Some Motor Functions In Parkinson's Disease Patients. C.g. Coimbra And V.b.c. Junqueira. Brazilian Journal Of Medical And Biological Research, 36: 1409-1417, 2003"

[No abstract available]37912971299Coimbra, C.G., Junqueira, V.B.C., High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients (2003) Brazilian Journal of Medical and Biological Research, 36, pp. 1409-1417Pare, S., Burr, S.I., Ross, S.E., Effect of day-time protein restriction on nutrient intakes of free-living Parkinson's disease patients (1992) American Journal of Clinical Nutrition, 55, pp. 701-707Simon, N., Gantcheva, R., Bruguerolle, B., Viallet, F., The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease (2004) Parkinsonism and Related Disorders, 10, pp. 137-142Fahn, S., Elton, R.L., Unified Parkinson's Disease Rating Scale (1987) Recent Developments in Parkinson's Disease, 2, pp. 153-164. , Members of the UPDRS Development Committee Fahn S, Marsden CD, Calne DB & Goldstein M (Editors), MacMillan Health Care Information, Florham Park, NJ, USABaldereschi, M., DiCarlo, A., Vanni, P., Ghetti, A., Carbonin, P., Amaducci, L., Inzitani, D., Italian longitudinal study on aging working group. Lifestyle related risk factors for Parkinson's disease: A populational study (2003) Acta Neurologica Scandinavica, 108, pp. 239-244Tsai, C.H., Lo, S.K., See, L.C., Chen, H.Z., Chen, R.S., Weng, Y.H., Chang, F.C., Lu, C.S., Environmental risk factors of young onset Parkinson's disease (2002) Clinical Neurology and Neurosurgery, 104, pp. 328-333Tanner, C.M., Epidemiological clues to the cause of Parkinson's disease (1994) Movement Disorders 3, pp. 124-146. , Marsden CD & Fahn S (Editors) Butterworth-Heinemann, Oxford, UKGolbe, L.I., Farrel, T.M., Davis, P.H., Case-control study of early life dietary factors in Parkinson's disease (1988) Archives of Neurology, 45, pp. 350-353Abbot, R.D., Ross, G.W., White, C.R., Sanderson, W.T., Burchfiel, C.M., Kashon, M., Sharp, D.S., Petrovitch, H., Environment, lifestyle, and physical precursors of clinical Parkinson's disease: Recent findings from the Honolulu-Asia aging study (2003) Journal of Neurology, 250 (SUPPL. 3), pp. III30-III3

Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis

PI3K activation plays a central role in the development of pulmonary inflammation and tissue remodeling. PI3K inhibitors may thus offer an improved therapeutic opportunity to treat non-resolving lung inflammation but their action is limited by unwanted on-target systemic toxicity. Here we present CL27c, a prodrug pan-PI3K inhibitor designed for local therapy, and investigate whether inhaled CL27c is effective in asthma and pulmonary fibrosis. Mice inhaling CL27c show reduced insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action. In murine models of acute or glucocorticoid-resistant neutrophilic asthma, inhaled CL27c reduces inflammation and improves lung function. Finally, inhaled CL27c administered in a therapeutic setting protects from bleomycin-induced lung fibrosis, ultimately leading to significantly improved survival. Therefore, local delivery of a pan-PI3K inhibitor prodrug reduces systemic on-target side effects but effectively treats asthma and irreversible pulmonary fibrosis